Amicus Therapeutics, Inc. (FOLD)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Amicus Therapeutics, Inc. (FOLD)
Go deeper and ask any question about FOLD
Company Performance
Current Price
as of Sep 13, 2024$11.30
P/E Ratio
N/A
Market Cap
$3.35B
Description
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Metrics
Overview
- HQPrinceton, NJ
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerFOLD
- Price$11.3+0.18%
Trading Information
- Market Cap$3.35B
- Float97.45%
- Average Daily Volume (1m)1,888,934
- Average Daily Volume (3m)2,585,294
- EPS-$0.40
Company
- Revenue$455.66M
- Rev Growth (1yr)34.04%
- Net Income-$15.70M
- Gross Margin89.39%
- EBITDA Margin13.54%
- EBITDA$17.15M
- EV$3.20B
- EV/Revenue7.02
- P/EN/A
- P/S7.53
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset